AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30304428
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B hemoperfusion plus standard therapy (n=224 patients)
Trial: 30304428
Drug: Sham hemoperfusion
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham hemoperfusion plus standard therapy (n=226 patients)
Trial: 30304428
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B hemoperfusion plus standard therapy (n=146 patients with MODS > 9)
Trial: 30304428
Drug: Sham hemoperfusion
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham hemoperfusion plus standard therapy (n=148 patients with MODS > 9)
Trial: 16215330
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy with specific adjuvant exercise
Trial: 16215330
Drug: Sham manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham manual therapy with specific adjuvant exercise
Trial: 2191977
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of autologous fibronectin with citric acid demineralisation
Trial: 30784233
Drug: Integrated preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated preventive psychological intervention (IPPI) and N-acetyl-l-cysteine (NAC)
Trial: 30784233
Drug: N-acetyl-l-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-l-cysteine (NAC) and psychological stress management
Trial: 23305133
Drug: Full-mouth disinfection
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth disinfection (FMD) group: full-mouth scaling and root planing (FMSRP) within 24 hours + local application of chlorhexidine (CHX) gel + CHX rinses for 60 days
Trial: 23305133
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: full-mouth scaling and root planing (FMSRP) within 24 hours + local application of placebo gel + placebo rinses for 60 days
Trial: 19702819
Drug: AmF-SnF2 mouth
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmF-SnF2 mouth rinse and toothpaste, used twice daily for 8 months
Trial: 19702819
Drug: Placebo mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouth rinse and toothpaste, used twice daily for 8 months
Trial: 16722802
Drug: Ketorolac 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.4% adjunctive regimen with cyclosporin-A
Trial: 16722802
Drug: Cyclosporin-A monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin-A monotherapy
Trial: 3770280
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion managed according to routine delivery unit practice (n = 36)
Trial: 3770280
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion rates halved (n = 45)
Trial: 3770280
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion rates quartered (n = 43)
Trial: 3770280
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion discontinued (n = 40)
Trial: 29145993
Drug: Synthetic bioabsorbable
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic bioabsorbable polymer spray
Trial: 26801483
Drug: Immunoadsorption (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IA) therapy using tryptophan column
Trial: 22513514
Drug: 3T optimized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3T optimized protocol (triple dose of Gd, 20 min scan delay)
Trial: 22513514
Drug: 1.5T standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5T standard protocol (single dose of Gd, 5 min scan delay)
Trial: 12051282
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% diclofenac (Group A)
Trial: 12051282
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone (Group B)
Trial: 7433477
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of methylglucamine indomethacinate (average dose 72.6 mg)
Trial: 7433477
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of methylglucamine indomethacinate (average dose 36.1 mg)
Trial: 22321682
Drug: Acellular tissue
RxNorm normalized name: ACELLULAR TISSUE ENGINEERED VESSEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular tissue matrix patch during Lichtenstein herniorrhaphy
Trial: 17493498
Drug: Timely administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timely administration of epinephrine
Trial: 15361183
Drug: Adjuvant platinum
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant platinum chemotherapy
Trial: 29108671
Drug: Metacognitive Reflection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive Reflection and Insight Therapy (MERIT‐EP)
Trial: 24853306
Drug: Adherence estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence estimated by pill count
Trial: 24853306
Drug: Drug detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug detection (tenofovir diphosphate or emtricitabine triphosphate)
Trial: 16389917
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of two approaches for adjustment
Trial: 8556568
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 micrograms twice daily for 2 weeks
Trial: 1971216
Drug: Dipipanone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipipanone (10 mg, oral)
Trial: 1971216
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (443C81 and dipipanone)
Trial: 28922226
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 80% oxygen
Trial: 28922226
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 30% oxygen
Trial: 24719126
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intracoronary abciximab and aspiration thrombectomy
Trial: 19620075
Drug: Patient-controlled epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled epidural analgesia (PCEA) with morphine
Trial: 15364776
Drug: Eptifibatide (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (IV bolus of 180 microg/kg body weight followed by continuous infusion of 2 microg/kg/min)
Trial: 8078528
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group, 153 subjects)
Trial: 8078528
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of adjustment in medications, behavioral instructions, and exercise programs (intervention group)
Trial: 10752815
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg/kg)
Trial: 1249566
Drug: Stimulant drug
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant drug treatment (continued medication)
Trial: 29441886
Drug: Mucosolvan® inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosolvan® inhalation in addition to conventional treatment
Trial: 29441886
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment only (Control)
Trial: 29441886
Drug: Mucosolvan® inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosolvan® inhalation
Trial: 25942443
Drug: Oral Valganciclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Valganciclovir (VGCV) 900mg/day
Trial: 25942443
Drug: Intravenous Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Ganciclovir (GCV) 5mg/kg twice daily
Trial: 22648280
Drug: Simulated soldier
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated soldier patrol (SP) at 42°C, 9% relative humidity for 2.5 hours with 400 mg ibuprofen
Trial: 22648280
Drug: Simulated soldier
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simulated soldier patrol (SP) at room temperature for 2.5 hours with 400 mg ibuprofen
Trial: 19090503
Drug: Ramelteon 16
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramelteon 16 mg nightly for 6 months
Trial: 11253266
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of acetylsalicylic acid (ASA) daily
Trial: 1588361
Drug: Simulated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simulated treatment group (cholesterol reduction)
Trial: 4002096
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 g of amoxicillin plus 1 g of probenecid (group 1)
Trial: 4002096
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of amoxicillin twice a day for two days (group 2)
Trial: 4002096
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg of amoxicillin three times a day for seven days (group 3)
Trial: 31863755
Drug: Preventive protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive protocol consisting of intermittent ventilation of the right lung, restoration of bilateral ventilation, administration of mannitol before unclamping the aorta, and institution of mild hypothermia.
Trial: 26712041
Drug: 0.5% AP736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% AP736 formulation (test formulation; n = 24)
Trial: 26712041
Drug: Vehicle formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle formulation (vehicle control; n = 24)
Trial: 25399731
Drug: Lisinopril and
RxNorm normalized name: lisinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril and ARB (telmisartan)
Trial: 19806411
Drug: Porous tantalum
RxNorm normalized name: tantalum
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porous tantalum implant
Trial: 18606612
Drug: cTnI levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cTnI levels >0.01 microg/L
Trial: 15748464
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U subcutaneously once weekly
Trial: 10730720
Drug: Implant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant treatment (preference)
Trial: 10730720
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (preference)
Trial: 9187986
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution (Group R, n = 20)
Trial: 9187986
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose (Group G, n = 20)
Trial: 2986424
Drug: hpGRF 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hpGRF 100 micrograms/h infusion for 2 to 5 hours after a bolus of 50 micrograms hpGRF
Trial: 30768188
Drug: Suboptimal care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal care (delays in antibiotics)
Trial: 29367653
Drug: Radiomic signature
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiomic signature derived from pre-therapy imaging using Intensity Direct and Neighbor Intensity Difference methods.
Trial: 25336707
Drug: Atosiban (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atosiban (6.75 mg bolus, followed by 18 mg/h for 1 hour, then 6 mg/h for 2 hours)
Trial: 12520569
Drug: Methylprednisolone 30
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 30 mg/kg 30 min before liver resection
Trial: 29855069
Drug: Standard splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard splint therapy
Trial: 21074013
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (buccal and sublingual)
Trial: 17621572
Drug: Acapella device
RxNorm normalized name: Acmella oleracea flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acapella device used for airway clearance sessions at home twice daily during oral antibiotic therapy (n=10)
Trial: 17621572
Drug: Usual airway
RxNorm normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual airway clearance sessions at home during oral antibiotic therapy (n=10)
Trial: 8536677
Drug: Gabapentin (GBP)
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin (GBP) at 900 mg/day or 1200 mg/day
Trial: 23325919
Drug: l‐[1‐(13)C]threonine enterally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐[1‐(13)C]threonine enterally or parenterally
Trial: 23325919
Drug: l‐[1‐(13)C]lysine enterally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐[1‐(13)C]lysine enterally or parenterally
Trial: 21295881
Drug: Reirradiation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reirradiation with various doses: 8 Gy single-dose, 5×3 Gy, 2×8 Gy, 5×4 Gy, single doses of 7 and 4 Gy.
Trial: 21295881
Drug: Reirradiation (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reirradiation (various doses)
Trial: 11148859
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (Zoltrix)
Trial: 9068312
Drug: One hour
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hour amphotericin B infusion
Trial: 9068312
Drug: Four hour
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four hour amphotericin B infusion
Trial: 3010692
Drug: Atropine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.04 mg/kg) with Propranolol
Trial: 3010692
Drug: Atropine (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.04 mg/kg) with Atenolol
Trial: 27217459
Drug: Nonmyeloablative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative chemotherapy with 1,200 cGy TBI
Trial: 27217459
Drug: Nonmyeloablative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonmyeloablative chemotherapy without TBI
Trial: 23526959
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment every three months for 21 months
Trial: 23526959
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment every three months for 21 months
Trial: 21169142
Drug: Fenoldopam (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam (0.2 μg/kg per minute)
Trial: 21169142
Drug: Dopexamine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopexamine (2 μg/kg per minute)
Trial: 12363466
Drug: Combined passive
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals) and Hepatitis B vaccine (arm I)
Trial: 12363466
Drug: Combined passive
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined passive active immunisation with human specific Hepatitis B immunoglobulin (HEPABIG‐VHB Pharmaceuticals)
Trial: 10364782
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard solution)
Trial: 8529068
Drug: Dopamine 1
RxNorm normalized name: DOPamine 160 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine 1 microgram/kg/min + Domperidone 30 mg
Trial: 7022973
Drug: E7H7 (ethambutol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E7H7 (ethambutol 15 mg/kg plus isoniazid 400 mg daily)
Trial: 7022973
Drug: E2H2 (ethambutol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2H2 (ethambutol 45 mg/kg plus isoniazid 15 mg/kg twice a week)
Trial: 7022973
Drug: E1H2 (ethambutol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1H2 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week plus isoniazid 15 mg/kg mid-way between the weekly doses)
Trial: 7022973
Drug: E1H1 (ethambutol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E1H1 (ethambutol 90 mg/kg plus isoniazid 15 mg/kg once a week)
Trial: 29231503
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (acupuncture and western medication)
Trial: 29231503
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (ribavirin granules 10 mg/kg a day, three times a day for 3 days)
Trial: 21476029
Drug: Ileal pouch-rectal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ileal pouch-rectal muscle sheath anastomosis
Trial: 18424129
Drug: (123)I‐mIBG positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (123)I‐mIBG positive metastatic disease after four chemotherapy cycles
Trial: 18424129
Drug: (123)I‐mIBG positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (123)I‐mIBG positive metastatic disease after six chemotherapy cycles
Trial: 11218246
Drug: Interferon-alpha2b (IFN-alpha2b)
RxNorm normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha2b (IFN-alpha2b) treatment
Trial: 9299856
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and dipyridamole (group B)
Trial: 9299856
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange and steroids without antiplatelet agents (group A)
Trial: 9299856
Drug: Ticlopidine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine maintenance therapy (after disease remission)
Trial: 8467430
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amantadine hydrochloride (100 mg, single oral dose)
Trial: 30292589
Drug: Lixisenatide (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (10-20 μg daily subcutaneous injection)
Trial: 22943927
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (fenofibrate and atorvastatin)
Trial: 18812609
Drug: Intravenous CNTO
RxNorm normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous CNTO 528
Trial: 8909669
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (0.15 mg/kg)
Trial: 2483556
Drug: Radical radiation
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical radiation and combination of bleomycin and 5-fluorouracil (5-FU)